Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Boosted by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 228.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 162,068 shares of the company’s stock after buying an additional 112,725 shares during the quarter. SG Americas Securities LLC’s holdings in Recursion Pharmaceuticals were worth $857,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its holdings in shares of Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after buying an additional 1,300 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after acquiring an additional 1,875 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after acquiring an additional 2,026 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Recursion Pharmaceuticals by 28.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock valued at $69,000 after acquiring an additional 2,235 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $5.11 on Friday. The stock has a market capitalization of $2.08 billion, a PE ratio of -2.89 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The business has a fifty day moving average price of $4.94 and a two-hundred day moving average price of $6.27. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RXRX. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Morgan Stanley decreased their price target on Recursion Pharmaceuticals from $8.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday. Finally, Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.